Switching from ranibizumab to aflibercept in age-related macular degeneration
Observes eye response after switching from ranibizumab to aflibercept injections in macular degeneration patients.
Plain-language title generated from the registry record
Registry title: Aflibercept in Recurrent or Persistent CNV
Key facts
- Where
- Vienna, AustriaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 or older with wet age-related macular degeneration who have already had ranibizumab eye injections for up to one year. They will switch to aflibercept.
- Age
- 50 years or older
- Sex
- All sexes can join.
- Disease stage
- Wet age-related macular degeneration that has come back or persists after ranibizumab treatment.
- Earlier treatment
- Treated with ranibizumab for wet age-related macular degeneration for up to one year.
- Biomarker or test result
- BCVA of 20/400 or better in the study eye on ETDRS charts.
Main reasons for not taking part
- Any eye surgery in the study eye within 3 months before the start
- Uncontrolled glaucoma in the study eye (eye pressure of 25 mmHg or more despite treatment)
- No lens (aphakia) or no back lens capsule in the study eye (YAG-capsulotomy excepted)
- Retinal pigment epithelial tear reaching the macula in the study eye
Read by machine on 12 November 2026.
Where in Austria
- Medical University of ViennaVienna, AustriaContact: Reinhard Told, MD, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Medical University of Vienna
- Trial code
- NCT02669953
- Record updated
- 26 November 2024
- Original description
Age-related macular degeneration (AMD) and diabetic retinopathy are among the most common disorders causing visual disability in elderly people. AMD leads to dysfunction and loss of photoreceptors in the central retina. Neovascular AMD (nAMD) affects visual function early in the disease process.Read full original descriptionShow less
Response to Aflibercept After Previous Intravitreal Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration
Age-related macular degeneration (AMD) and diabetic retinopathy are among the most common disorders causing visual disability in elderly people. AMD leads to dysfunction and loss of photoreceptors in the central retina. Neovascular AMD (nAMD) affects visual function early in the disease process.
The purpose of the study is to evaluate the effect of switching from ranibizumab therapy to the current routine therapy using aflibercept in eyes with treatment naive, recurrent or persistent nAMD, treatment naive diabetic retinopathy and pretreated diabetic retinopathy.
20 patients with recurrent or persistent nAMD, previously treated with intravitreal ranibizumab for up to one year will be included in this trial. Patients will be examined in monthly intervals over 12 months follow-up.
Examinations carried out will include: Best-corrected visual acuity (BCVA) using ETDRS charts at 4m distance, Reading Performance (RP), Standard ophthalmic examinations (SOE incl. funduscopy and applanation tonometry), Optical coherence tomography (OCT), Autofluorescence fundus image (AF) \& red-free autofluorescence fundus image (RF), Color fundus photography (CFP), Fluorescein angiography and indocyaningreen angiography (FLA/ICG), Microperimetry (MP), as well as Non-invasive OCT based optical angiography (AngioVue).
Inclusion: Adults ≥ 50 years; Patients who have been treated with ranibizumab due to wet age-related macular degeneration for up to one year; BCVA >= 20/400 in the study eye using ETDRS; Willingness and ability to comply with regular visits; Signed informed consent.
Exclusion: Any surgical treatment of the eye within 3 months prior to baseline in the study eye; History of uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma mediation); Aphakia or absence of the posterior capsule (excluding YAG-capsulotomy) in the study eye; Retinal pigment epithelial tear involving the macula in the study eye.